Where Faith Meets Business Excellence
Leadership Memo 2025-5 Last month, we explored how Bayer’s Dynamic Shared Ownership (DSO) transformation has been going after one year. This time, let’s take a closer look at how DSO really works in everyday practice. CEO Bill Anderson points to…
Read More The Ownership Shift: What Bayer’s DSO Teaches Us About Leading Differently
Leadership Memo 2025-4 Last year, I wrote a mini-series on Bayer's audacious corporate experiment under CEO Bill Anderson. A year has passed. Let’s see how this bold venture is faring. Let me refresh your memory. Bayer is a US$50 billion…
Read More From Bureaucracy to Breakthrough: Bayer’s DSO Revolution in Year One
Leadership Memo 2024-9 Over the past few months, we've been following Bill Anderson's audacious strategy to revitalize Bayer, the struggling German pharmaceutical giant. At the heart of this corporate experiment lies Dynamic Shared Ownership (DSO), a corporate experiment unlike any…
Read More Bayer’s New Model: Bill Anderson’s Vision and Early Results
Leadership Memo 2024-8 In recent months, I introduced you to the most audacious corporate experiment in recent years: Dynamic Shared Ownership (DSO). DSO is Bill Anderson’s bold strategy to revive Bayer, the struggling German pharmaceutical giant. I’ve explained what DSO…
Read More Beyond Hierarchies: The Challenges and Promise of Bayer’s Decentralization Strategy
Leadership Memo 2024-7 In April, I introduced you to the most audacious corporate experiment in recent years: Dynamic Shared Ownership (DSO). DSO is Bill Anderson’s answer to fighting bureaucracy. It’ll allow his company, the German pharmaceutical goliath Bayer, to get…
Read More Meet Bill Anderson: The Man Behind Bayer’s Bold Move Towards Agility
Leadership Memo 2024-6 In April, I introduced you to the most audacious corporate experiment in recent years: Dynamic Shared Ownership (DSO). DSO is Bill Anderson’s approach to fighting bureaucracy, the sinister force weighing on the company’s strategic options, and allowing…
Read More Busting Bureaucracy: Bayer’s Bold Bet on Dynamic Shared Ownership
Leadership Memo 2024-4 Imagine the challenges facing a US$50 billion multi-national company with a 160-year history: share price at a 20-year low (down 50% from a year ago), litigation, high debt, and losing patents on some of their most important…
Read More Want to take a peek at the most audacious corporate experiment?
